Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 140.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 40,356 shares of the company's stock after acquiring an additional 23,550 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.10% of Keros Therapeutics worth $639,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Keros Therapeutics by 5.4% in the 4th quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock worth $30,981,000 after buying an additional 100,691 shares during the period. Geode Capital Management LLC grew its stake in shares of Keros Therapeutics by 5.5% during the 4th quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock worth $12,120,000 after purchasing an additional 39,815 shares during the period. Lynx1 Capital Management LP acquired a new stake in shares of Keros Therapeutics during the 4th quarter worth approximately $8,612,000. American Century Companies Inc. grew its stake in shares of Keros Therapeutics by 10.5% during the 4th quarter. American Century Companies Inc. now owns 328,920 shares of the company's stock worth $5,207,000 after purchasing an additional 31,251 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Keros Therapeutics by 7.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 279,682 shares of the company's stock worth $4,427,000 after purchasing an additional 19,562 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Down 0.7%

KROS stock opened at $14.04 on Thursday. The business has a 50 day moving average price of $12.58 and a 200 day moving average price of $22.18. The stock has a market cap of $570.23 million, a price-to-earnings ratio of -2.69 and a beta of 1.32. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $3.63. The firm had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same quarter in the previous year, the business earned ($1.21) earnings per share. As a group, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of Keros Therapeutics stock in a transaction on Wednesday, April 9th. The stock was bought at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. This represents a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 20.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. HC Wainwright dropped their price objective on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Truist Financial dropped their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Wedbush reiterated a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Wells Fargo & Company decreased their target price on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. Finally, Scotiabank decreased their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $37.00.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.